Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johan Burisch

Showing results (1-10 of 272) with videos related to

Pageof 28
Sort By:
Alimentary Pharmacology & Therapeutics|April 13, 2023
Editorial: Why are patients with Crohn's disease still treated with 5-aminosalicylates?Johan Burisch
APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica|June 19, 2023
Long-term disease course, cost and prognosis of inflammatory bowel disease: epidemiological studies of a European and a Danish inception cohortJohan Burisch
United European Gastroenterology Journal|February 6, 2015
Rejuvenating UEG: The Young Talent Group and the Young GI NetworkJohan Burisch
Ugeskrift for Laeger|June 20, 2025
Johan Burisch
Journal of Crohn'S & Colitis|July 14, 2022
The Impact of Anti-tumour Necrosis Factor Alpha Agents on the Risk of Colorectal CancerJohan Burisch
United European Gastroenterology Journal|January 19, 2023
Is hypertension an extra-intestinal manifestation of inflammatory bowel disease?Johan Burisch
Alimentary Pharmacology & Therapeutics|September 7, 2022
Editorial: trends in the epidemiology of inflammatory bowel disease in KoreaJohan Burisch
Danish Medical Journal|January 8, 2014
Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohortJohan Burisch
Gastroenterology|March 29, 2026
Re-induction or Redirection? Lessons From the REScUE Trial on Ustekinumab Intensification in Crohn's DiseaseJohan Burisch
Journal of Crohn'S & Colitis|June 20, 2020
The Sooner the Better? Cost-effectiveness of Early Biological Therapy in Patients With Crohn's DiseaseMirabella Zhao, Johan Burisch
Pageof 28

Showing results (1-10 of 272) with videos related to

Sort By:
Pageof 28
Alimentary Pharmacology & Therapeutics|April 13, 2023
Editorial: Why are patients with Crohn's disease still treated with 5-aminosalicylates?Johan Burisch
APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica|June 19, 2023
Long-term disease course, cost and prognosis of inflammatory bowel disease: epidemiological studies of a European and a Danish inception cohortJohan Burisch
United European Gastroenterology Journal|February 6, 2015
Rejuvenating UEG: The Young Talent Group and the Young GI NetworkJohan Burisch
Ugeskrift for Laeger|June 20, 2025
Johan Burisch
Journal of Crohn'S & Colitis|July 14, 2022
The Impact of Anti-tumour Necrosis Factor Alpha Agents on the Risk of Colorectal CancerJohan Burisch
United European Gastroenterology Journal|January 19, 2023
Is hypertension an extra-intestinal manifestation of inflammatory bowel disease?Johan Burisch
Alimentary Pharmacology & Therapeutics|September 7, 2022
Editorial: trends in the epidemiology of inflammatory bowel disease in KoreaJohan Burisch
Danish Medical Journal|January 8, 2014
Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohortJohan Burisch
Gastroenterology|March 29, 2026
Re-induction or Redirection? Lessons From the REScUE Trial on Ustekinumab Intensification in Crohn's DiseaseJohan Burisch
Journal of Crohn'S & Colitis|June 20, 2020
The Sooner the Better? Cost-effectiveness of Early Biological Therapy in Patients With Crohn's DiseaseMirabella Zhao, Johan Burisch
Pageof 28